Development of a low cost, point-of-care diagnostic test to prevent abacavir hypersensitivity
Group LeaderProfessor Patrick Kwan
T: +61 3 9342 7722
Location: Royal Melbourne Hospital
Abacavir is a nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. 5-8% people develop hypersensitivity to abacavir. It has been found that abacavir hypersensitivity is strongly associated with HLA-B*57:01, and pre-therapy HLA testing is recommended by regulatory agencies and all major treatment guidelines. However, conventional testing is laboratory based with long turnaround time and is not accessible or affordable for people living in developing countries where many people with HIV live.
A monoclonal antibody that recognises HLA-B*57:01 has been developed. This project aims to use this antibody to develop a simple, rapid, low cost HLA-B*57:01 test kit.
- Prof Stan Skafidas
This research project is available to PhD students to join as part of their thesis.
Please contact the Research Group Leader to discuss your options.